TY - JOUR
T1 - Echocardiography-Guided Percutaneous Patent Ductus Arteriosus Closure
T2 - 1-Year Single Center Experience in Indonesia
AU - Siagian, Sisca Natalia
AU - Prakoso, Radityo
AU - Putra, Bayushi Eka
AU - Kurniawati, Yovi
AU - Lelya, Olfi
AU - Sembiring, Aditya Agita
AU - Atmosudigdo, Indriwanto Sakidjan
AU - Roebiono, Poppy Surwianti
AU - Rahajoe, Anna Ulfah
AU - Harimurti, Ganesja Moelia
AU - Mendel, Brian
AU - Christianto, Christianto
AU - Setiawan, Moira
AU - Lilyasari, Oktavia
N1 - Funding Information:
We would like to thank those who have supported us in the making of this study. We are especially grateful to the Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, for their guidance and assistance in teaching the authors about research methodology and for proofreading this article.
Publisher Copyright:
Copyright © 2022 Siagian, Prakoso, Putra, Kurniawati, Lelya, Sembiring, Atmosudigdo, Roebiono, Rahajoe, Harimurti, Mendel, Christianto, Setiawan and Lilyasari.
PY - 2022/5/23
Y1 - 2022/5/23
N2 - Introduction: Since the first successful percutaneous closure under transesophageal echocardiographic (TEE) guidance, many centers explored transcatheter procedures without fluoroscopy. This single-center study is aimed to show the feasibility and safety of percutaneous patent ductus arteriosus (PDA) closure under echocardiography-only guidance during our 1-year experience. Methods: Patients with PDA were recruited for percutaneous PDA closure guided by either fluoroscopy or echocardiography-only in National Cardiovascular Center Harapan Kita (ClinicalTrials.gov Identifier: NCT05321849, clinicaltrials.gov/ct2/show/NCT05321849). Patients were evaluated clinically and radiologically using transthoracic echocardiography (TTE) at 6, 24, and 48 h after the procedure. The primary endpoint was the procedural success. Secondary endpoints were the procedural time and the rate of adverse events. Results: A total of 60 patients underwent transcatheter PDA closure, 30 patients with fluoroscopy and 30 patients with echocardiography guidance. All patients had successful PDA closure. There were only residual shunts, which were disappeared after follow-up in both groups, but one patient with a fluoroscopy-guided procedure had moderate tricuspid regurgitation with suspected thrombus in the tricuspid valve. The procedural time was not significantly different between the fluoroscopy and echocardiography groups.
AB - Introduction: Since the first successful percutaneous closure under transesophageal echocardiographic (TEE) guidance, many centers explored transcatheter procedures without fluoroscopy. This single-center study is aimed to show the feasibility and safety of percutaneous patent ductus arteriosus (PDA) closure under echocardiography-only guidance during our 1-year experience. Methods: Patients with PDA were recruited for percutaneous PDA closure guided by either fluoroscopy or echocardiography-only in National Cardiovascular Center Harapan Kita (ClinicalTrials.gov Identifier: NCT05321849, clinicaltrials.gov/ct2/show/NCT05321849). Patients were evaluated clinically and radiologically using transthoracic echocardiography (TTE) at 6, 24, and 48 h after the procedure. The primary endpoint was the procedural success. Secondary endpoints were the procedural time and the rate of adverse events. Results: A total of 60 patients underwent transcatheter PDA closure, 30 patients with fluoroscopy and 30 patients with echocardiography guidance. All patients had successful PDA closure. There were only residual shunts, which were disappeared after follow-up in both groups, but one patient with a fluoroscopy-guided procedure had moderate tricuspid regurgitation with suspected thrombus in the tricuspid valve. The procedural time was not significantly different between the fluoroscopy and echocardiography groups.
KW - congenital heart disease
KW - echocardiography
KW - fluoroscopy
KW - patent ductus arteriosus
KW - percutaneous
UR - http://www.scopus.com/inward/record.url?scp=85138600361&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2022.885140
DO - 10.3389/fcvm.2022.885140
M3 - Article
AN - SCOPUS:85138600361
SN - 2297-055X
VL - 9
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 885140
ER -